Skip to main content

FIGHTING-OFF CORONAVIRUS (SARS-CoV-2) WITH BROAD-SPECTRUM ANTIVIRALS: ESTABLISHING ANIMAL VIRAL CHALLENGE MODEL

Project description

New intranasal drugs against SARS-CoV-2

The extent of the current COVID-19 pandemic demands concerted efforts towards effective diagnostics, therapies and vaccines. In this direction, the EU-funded Fight-nCoV project will accelerate the preclinical development of new broad-spectrum antivirals administered via inhalation. The work builds on ongoing research on drugs that block viral entry and will test their safety and activity against SARS-CoV-2 in a macaque model of the disease. The efficacy information on these intranasal inhibitors in non-human primates will lay the foundation for the next step in the development pipeline of these drugs for human use.

Call for proposal

H2020-SC1-PHE-CORONAVIRUS-2020
See other projects for this call

Coordinator

STOCKHOLMS UNIVERSITET
Address
Universitetsvagen 10
10691 Stockholm
Sweden
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 842 937,50

Participants (5)

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
France
EU contribution
€ 674 000
Address
Rue Leblanc 25
75015 Paris 15
Activity type
Research Organisations
UNIVERSITAET ULM
Germany
EU contribution
€ 360 000
Address
Helmholtzstrasse 16
89081 Ulm
Activity type
Higher or Secondary Education Establishments
AARHUS UNIVERSITET
Denmark
EU contribution
€ 144 226,25
Address
Nordre Ringgade 1
8000 Aarhus C
Activity type
Higher or Secondary Education Establishments
ADLEGO BIOMEDICAL AB
Sweden
EU contribution
€ 620 588,50
Address
Box 42
751 03 Uppsala
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAET DUISBURG-ESSEN
Germany
EU contribution
€ 165 273,75
Address
Universitatsstrasse 2
45141 Essen
Activity type
Higher or Secondary Education Establishments